February 29, 2020 / 1:40 AM / a month ago

BRIEF-Abbvie Provides Update From Phase 3 Study Evaluating Venclexta In Combination With Low-Dose Cytarabine In Newly-Diagnosed Patients With Acute Myeloid Leukemia

Feb 28 (Reuters) - Abbvie Inc:

* ABBVIE PROVIDES UPDATE FROM PHASE 3 STUDY EVALUATING VENCLEXTA® (VENETOCLAX) IN COMBINATION WITH LOW-DOSE CYTARABINE IN NEWLY-DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

* ABBVIE-PHASE 3 VIALE-A TRIAL EVALUATING VENETOCLAX IN COMBINATION WITH AZACYTIDINE IS ONGOING, AT THIS TIME INDICATIONS FOR VENETOCLAX REMAIN UNCHANGED

* ABBVIE - STUDY EVALUATING VENCLEXTA DID NOT DEMONSTRATE STATISTICALLY SIGNIFICANT IMPROVEMENT IN PRIMARY ENDPOINT OF OVERALL SURVIVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below